NASDAQ:JSPR

Jasper Therapeutics Q3 2026 Earnings Results & Report

Jasper Therapeutics logo
$11.23 -0.54 (-4.59%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Jasper Therapeutics missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$10.19 versus the -$1.77 consensus estimate, while revenue of $8 million topped the $6 million estimate by $2 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
8:00 AM ET

Jasper Therapeutics EPS Results

Actual EPS
-$10.19
Consensus EPS
-$1.77
Beat/Miss
Missed by -$8.42
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Jasper Therapeutics Revenue Results

Actual Revenue
$8 million
Expected Revenue
$6 million
Beat/Miss
Beat by +$2.00 million
YoY Revenue Growth
N/A

Jasper Therapeutics Q3 2026 Earnings FAQ

Jasper Therapeutics (NASDAQ:JSPR) reported earnings of -$10.19 per share for Q3 2026, missing the consensus estimate of -$1.77. The report was announced on Monday, November 16, 2026.

Jasper Therapeutics reported revenue of $8 million for Q3 2026, against a consensus estimate of $6 million.

Jasper Therapeutics Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Wall Street Zen
Jasper Therapeutics (NASDAQ:JSPR) Shares Gap Down - Time to Sell?
See More Jasper Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email.

About Jasper Therapeutics

Jasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells.

The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria. The drug is investigational and is not approved for commercial use.

Jasper is based in the United States and conducts clinical-stage drug development. Its programs are intended to address unmet medical needs in areas including rare blood disorders and allergic or inflammatory conditions.

View Jasper Therapeutics Profile